Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that CD30 + status confers therapeutic sensitivity to Brentuximab Vedotin, Dacarbazine, Doxorubicin, Vinblastine in patients with Hodgkin Lymphoma.
The European Medicines Agency (EMA) has authorized brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine for the treatment of adult patients with previously untreated CD30+ stage III or IV Hodgkin lymphoma (HL).
This statement is based on a regulatory approval from the European Medicines Agency:
ADCETRIS is indicated for adult patients with previously untreated CD30+ Stage III or IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD).